Smell impairment in patients with chronic rhinosinusitis: a real-life study

Passàli, Giulio Cesare; Passàli, Desiderio; Cingi, Cemal; Ciprandi, Giorgio

doi:10.1007/s00405-021-06848-9

Cited by 19 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depending on the number of correctly identified substances, a result between 0 (no substance identified) and 16 (all substances identified) is obtained. This allowed us to classify patients as anosmic (score between 0 and 5), hyposmic (score between 6 and 10), or normosmic (score between 11 and 16) [ 12 , 13 , 14 ].…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A “Real-Life” Observational Study in the First Year of Treatment

Corso

Settimi

Montuori

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), with or without asthma as add-on therapy with intra-nasal corticosteroids in a real-life setting over the first year of treatment. Our data demonstrated that subcutaneous 300 mg dupilumab administered at home via a pre-filled auto-injector every two weeks, based on indications set by the Italian Medicines Agency, was rapidly effective in reducing the size of polyps, decreasing symptoms of disease, improving quality of life, and recovering olfaction. Significant improvement was observed after only 15 days of treatment, and it progressively increased at 6 and 12 months. Dupilumab was also effective in reducing the local nasal eosinophilic infiltrate, in decreasing the need for surgery and/or oral corticosteroids, and in improving control of associated comorbidities such as chronic eosinophilic otitis media and bronchial asthma. After 12 months of treatment, 96.5% of patients had a moderate/excellent response. From our data, it was evident that there was a group of patients that showed a very early response within one month of therapy, another group with early response within six months from baseline, and a last group that improved later within 12 months. The results of this study support the use of dupilumab as an effective option in the current standard of care for patients affected by severe uncontrolled CRSwNP.

show abstract

Section: Methodsmentioning

confidence: 99%

Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A “Real-Life” Observational Study in the First Year of Treatment

Corso

Settimi

Montuori

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…The identification score corresponds to the number of correct responses out of 16 total score. The results were associated with smell function as follows: 0-5 anosmia, 6-11 hyposmia, and 12-16 normal smell [22].…”

mentioning

confidence: 98%

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP

Corso

Montuori

Settimi

et al. 2022

JCM

View full text Add to dashboard Cite

Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media characterized by eosinophilic accumulation in the middle ear mucosa and effusion. It is resistant to conventional treatments and strongly associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of our study is to evaluate the effectiveness of biologics drugs in the control of EOM. This is a retrospective no-profit real-life observational study, involving patients affected by refractory EOM and in treatment with different biologics for concomitant severe eosinophilic asthma or severe uncontrolled CRSwNP (Dupilumab: n = 5; Omalizumab: n = 1; Mepolizumab: n = 1; Benralizumab: n = 1). We analyzed data at baseline and at the 6-month follow-up, including specific nasal and otological parameters. We observed an improvement of all nasal outcomes, including NPS, SNOT-22, VAS, and smell function. Regarding specific otological parameters, we observed a significant reduction in the mean value of COMOT-15 score and of Otitis Severity Score at 6-month follow-up compared to baseline (p < 0.05). Finally, we observed an improvement in terms of air conduction hearing levels during the treatment. Our results demonstrated that anti type-2 inflammatory pathway biologics can be effective in improving symptoms control and in reducing the severity of eosinophilic otitis media when treating coexisting type-2 diseases, such as asthma and or CRSwNP.

show abstract

“…C, s., g, i., g, f.-e., s, s., v, e., , 2002 , Lucero, 2013 , Passali et al, 2022 , Schirinzi et al, 2021c .…”

Section: Uncited Referencesunclassified

Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction

Schirinzi¹,

Lattanzi²,

Maftei³

et al. 2023

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Smell impairment in patients with chronic rhinosinusitis: a real-life study

Cited by 19 publications

References 30 publications

Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A “Real-Life” Observational Study in the First Year of Treatment

Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A “Real-Life” Observational Study in the First Year of Treatment

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP

Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction

Contact Info

Product

Resources

About